

**CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS**

**APPLICATION PEDIGREE**

Date and time exported: 05/24/2023 01:37 PM CT

**FY:** 2023  
**CYCLE:** 1  
**PROGRAM:** Product Development  
**MECHANISM:** Texas Therapeutics Company Full Awards for Product Development Research  
**APPLICATION ID:** DP230062  
**APPLICATION TITLE:** 7HP349, a Small Molecule, Oral Integrin Activator to Treat Patients With anti-PD-1 Resistant Melanoma  
**APPLICANT NAME:** Lewis, Lionel D  
**ORGANIZATION:** 7 Hills Pharma LLC  
**PANEL NAME:** 23.1 Product Development Panel-1

Category	Compliance Requirement	Information	Attestation Date	
<b>Pre-Receipt</b>	RFA approved by CPDO	08/24/2022	01/23/2023	
	RFA approved by CPDO (revised)	10/10/2022	01/23/2023	
	RFA approved by CPDO (2nd revision)	02/01/2023	02/01/2023	
	RFA published in Texas.gov eGrants	08/25/2022	01/23/2023	
	CPRIT Application Receipt System (CARS) opened	08/24/2022	01/23/2023	
	CPRIT Application Receipt System closed - Cycle 1	11/01/2022	01/24/2023	
	CPRIT Application Receipt System (CARS) closed	01/23/2023	01/24/2023	
	Date application submitted	10/14/2022	01/24/2023	
	Method of submission	CARS	01/24/2023	
	Within receipt period	YES	01/24/2023	
	Request for extension to submit application after CARS closed	N/A	01/24/2023	
	Request for extension for late application submission accepted	N/A	01/24/2023	
	Submission of application fee	YES	05/04/2023	
	<b>Receipt, Referral, and Assignment</b>	Administrative review notification	N/A	01/24/2023
Donation(s) made to CPRIT / foundation		NO	01/24/2023	
Assigned to primary reviewers		11/10/2022	01/24/2023	
Applicant notified of review panel assignment		11/08/2022	01/24/2023	
Primary Reviewer 1 COI signed		11/09/2022	01/24/2023	
Primary (Advocate) Reviewer 2 COI signed		11/04/2022	01/24/2023	
Primary Reviewer 3 COI signed		11/08/2022	01/24/2023	
Primary Reviewer 4 COI signed		11/04/2022	01/24/2023	
Primary Reviewer 5 COI signed		11/06/2022	01/24/2023	
Primary Reviewer 6 COI signed		11/04/2022	01/24/2023	
Primary Reviewer 7 COI signed		11/05/2022	01/24/2023	
<b>Peer Review Meeting</b>		Primary Reviewer 1 critique submitted	11/27/2022	01/24/2023
		Primary (Advocate) Reviewer 2 critique submitted	11/21/2022	01/24/2023
	Primary Reviewer 3 critique submitted	11/26/2022	01/24/2023	
	Primary Reviewer 4 critique submitted	11/27/2022	01/24/2023	
	Primary Reviewer 5 critique submitted	11/15/2022	01/24/2023	
	Primary Reviewer 6 critique submitted	11/27/2022	01/24/2023	
	Primary Reviewer 7 critique submitted	11/25/2022	01/24/2023	
	COI indicated by non-primary reviewer	NONE	01/24/2023	
	COI recused from participation	N/A	01/24/2023	
	Peer Review Meeting	12/12/2022	01/24/2023	
	Post review statements signed	12/12/2022	01/23/2023	
	Third Party Observer Report	12/21/2022	01/17/2023	
	Score report delivered to CPDO	12/20/2022	01/23/2023	
Recommended for due diligence and IP review	YES	01/24/2023		
<b>Due Diligence and IP Review</b>	Final due diligence review submitted to PDRC	01/06/2023	03/22/2023	
	Intellectual Property conflict check	12/02/2022	03/22/2023	
	Final intellectual property review submitted	01/06/2023	03/22/2023	
	COI indicated by reviewer	NONE	01/24/2023	
	COI recused from participation	N/A	01/24/2023	
	Due Diligence Meeting	01/13/2023	01/24/2023	
	Third Party Observer Report	01/18/2023	01/24/2023	
	Recommended for grant award	YES	01/24/2023	
<b>Final PDRC Recommendation</b>	COI indicated by PDRC member	N/A	01/24/2023	
	COI indicated by PDRC member	Elaine Jones	01/24/2023	
	COI recused from participation	YES	01/24/2023	
	Due Diligence Evaluation Meeting / PDRC Meeting	N/A	01/23/2023	
	PDRC Meeting	01/23/2023	01/23/2023	
	Third Party Observer Report	01/25/2023	02/07/2023	
	Recommended for grant award	YES	01/24/2023	
	PDRC Chair Notification to PIC and OC	01/30/2023	02/07/2023	
<b>PIC Review</b>	COI indicated by PIC member	N/A	05/03/2023	
	COI recused from participation	N/A	05/03/2023	
	PIC Review Meeting	02/01/2023	05/03/2023	
	Recommended for grant award	Other: Deferred	05/03/2023	
	COI Indicated by PIC member	None	05/04/2023	
	COI recused from participation	N/A	05/04/2023	
	PIC Review Meeting	05/03/2023	05/04/2023	
	Recommended for grant award	YES	05/04/2023	
<b>Oversight Committee Approval</b>	CEO Notification to Oversight Committee	05/08/2023	05/18/2023	
	COI Indicated by Oversight Committee member	None	05/18/2023	
	COI Recused from participation	N/A	05/18/2023	
	Donation(s) made to CPRIT / foundation	NO	05/18/2023	
	Presented to CPRIT Oversight Committee	05/17/2023	05/18/2023	
	Award approved by Oversight Committee	YES	05/18/2023	
	Authority to advance funds requested	YES	05/18/2023	
	Advance authority approved by Oversight Committee	YES	05/18/2023	
Comments:				
Comment				
Updated status on 1/18/23 to reflect new review process: Peer Review meeting to Due Diligence meeting.				

**CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS**

**APPLICATION PEDIGREE**

Date and time exported: 05/24/2023 01:37 PM CT

**FY:** 2023  
**CYCLE:** 1  
**PROGRAM:** Product Development  
**MECHANISM:** Seed Full Awards for Product Development Research  
**APPLICATION ID:** DP230064  
**APPLICATION TITLE:** IND-Enabling Studies of ONP-001: A Nano-Codelivery Formulation with Two Drugs of Distinct Mechanisms of Action for Treating Pancreatic Ductal Adenocarcinoma  
**APPLICANT NAME:** Ma, Guorong  
**ORGANIZATION:** OmniNano Pharmaceuticals LLC  
**PANEL NAME:** 23.1 Product Development Panel-5

Category	Compliance Requirement	Information	Attestation Date	
<b>Pre-Receipt</b>	RFA approved by CPDO	08/24/2022	01/23/2023	
	RFA approved by CPDO (revised)	10/10/2022	01/23/2023	
	RFA approved by CPDO (2nd revision)	02/01/2023	02/01/2023	
	RFA published in Texas.gov eGrants	08/25/2022	01/24/2023	
	CPRIT Application Receipt System (CARS) opened	08/24/2022	01/23/2023	
	CPRIT Application Receipt System closed - Cycle 1	11/01/2022	01/24/2023	
	CPRIT Application Receipt System (CARS) closed	01/23/2023	01/24/2023	
	Date application submitted	10/31/2022	01/24/2023	
	Method of submission	CARS	01/24/2023	
	Within receipt period	YES	01/24/2023	
	Request for extension to submit application after CARS closed	N/A	01/24/2023	
	Request for extension for late application submission accepted	N/A	01/24/2023	
	Submission of application fee	YES	05/04/2023	
	<b>Receipt, Referral, and Assignment</b>	Administrative review notification	N/A	01/24/2023
		Donation(s) made to CPRIT / foundation	NO	01/24/2023
Assigned to primary reviewers		11/09/2022	01/24/2023	
Applicant notified of review panel assignment		11/08/2022	01/24/2023	
Primary Reviewer 1 COI signed		11/04/2022	01/24/2023	
Primary (Advocate) Reviewer 2 COI signed		11/04/2022	01/24/2023	
Primary Reviewer 3 COI signed		11/09/2022	01/24/2023	
Primary Reviewer 4 COI signed		11/04/2022	01/24/2023	
Primary Reviewer 5 COI signed		11/08/2022	01/24/2023	
Primary Reviewer 6 COI signed		11/05/2022	01/24/2023	
Primary Reviewer 7 COI signed		11/04/2022	01/24/2023	
Primary Reviewer 8 COI signed		11/07/2022	01/24/2023	
Primary Reviewer 9 COI signed		11/06/2022	01/24/2023	
Primary Reviewer 10 COI signed		11/07/2022	01/24/2023	
<b>Peer Review Meeting</b>		Primary Reviewer 1 critique submitted	11/19/2022	01/24/2023
	Primary (Advocate) Reviewer 2 critique submitted	11/21/2022	01/24/2023	
	Primary Reviewer 3 critique submitted	11/27/2022	01/24/2023	
	Primary Reviewer 4 critique submitted	11/20/2022	01/24/2023	
	Primary Reviewer 5 critique submitted	11/28/2022	01/24/2023	
	Primary Reviewer 6 critique submitted	11/22/2022	01/24/2023	
	Primary Reviewer 7 critique submitted	11/27/2022	01/24/2023	
	Primary Reviewer 8 critique submitted	11/15/2022	01/24/2023	
	Primary Reviewer 9 critique submitted	11/26/2022	01/24/2023	
	Primary Reviewer 10 critique submitted	11/28/2022	01/24/2023	
	COI indicated by non-primary reviewer	NONE	01/24/2023	
	COI recused from participation	N/A	01/24/2023	
	Peer Review Meeting	12/14/2022	01/24/2023	
	Post review statements signed	12/14/2022	01/24/2023	
	Third Party Observer Report	12/21/2022	01/17/2023	
Score report delivered to CPDO	12/20/2022	01/24/2023		
Recommended for due diligence and IP review	YES	01/24/2023		
<b>Due Diligence and IP Review</b>	Final due diligence review submitted to PDRC	01/06/2023	03/22/2023	
	Intellectual Property conflict check	12/02/2022	03/22/2023	
	Final intellectual property review submitted	01/06/2023	03/22/2023	
	COI indicated by reviewer	NONE	01/24/2023	
	COI recused from participation	N/A	01/24/2023	
	Due Diligence Meeting	01/19/2023	01/24/2023	
	Third Party Observer Report	01/25/2023	03/24/2023	
Recommended for grant award	YES	01/24/2023		
<b>Final PDRC Recommendation</b>	COI indicated by PDRC member	NONE	01/24/2023	
	COI recused from participation	N/A	01/24/2023	
	Due Diligence Evaluation Meeting / PDRC Meeting	N/A	01/24/2023	
	PDRC Meeting	01/23/2023	01/24/2023	
	Third Party Observer Report	01/25/2023	02/07/2023	
	Recommended for grant award	YES	01/24/2023	
	PDRC Chair Notification to PIC and OC	01/30/2023	02/07/2023	
<b>PIC Review</b>	COI indicated by PIC member	N/A	05/03/2023	
	COI recused from participation	N/A	05/03/2023	
	PIC Review Meeting	02/01/2023	05/03/2023	
	Recommended for grant award	Other: Deferred	05/03/2023	
	COI indicated by PIC member	None	05/04/2023	
	COI recused from participation	N/A	05/04/2023	
	PIC Review Meeting	05/03/2023	05/04/2023	
	Recommended for grant award	YES	05/04/2023	
<b>Oversight Committee Approval</b>	CEO Notification to Oversight Committee	05/08/2023	05/18/2023	
	COI Indicated by Oversight Committee member	None	05/18/2023	
	COI Recused from participation	N/A	05/18/2023	
	Donation(s) made to CPRIT / foundation	NO	05/18/2023	
	Presented to CPRIT Oversight Committee	05/17/2023	05/18/2023	
	Award approved by Oversight Committee	YES	05/18/2023	
	Authority to advance funds requested	YES	05/18/2023	
	Advance authority approved by Oversight Committee	YES	05/18/2023	



**CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS**

**APPLICATION PEDIGREE**

Date and time exported: 05/24/2023 01:37 PM CT

FY: 2023  
 CYCLE: 1  
 PROGRAM: Product Development  
 MECHANISM: Texas Therapeutics Company Full Awards for Product Development Research  
 APPLICATION ID: DP230066  
 APPLICATION TITLE: Improving Cancer Patient Outcomes by Activating Lung Innate Immunity  
 APPLICANT NAME: Scott, Brenton  
 ORGANIZATION: Pulmotect, Inc.  
 PANEL NAME: 23.1 Product Development Panel-3

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA approved by CPDO	08/24/2022	01/23/2023
	RFA approved by CPDO (revised)	10/10/2022	01/23/2023
	RFA approved by CPDO (2nd revision)	02/01/2023	02/01/2023
	RFA published in Texas.gov eGrants	08/25/2022	01/23/2023
	CPRIT Application Receipt System (CARS) opened	08/24/2022	01/23/2023
	CPRIT Application Receipt System closed - Cycle 1	11/01/2022	01/24/2023
	CPRIT Application Receipt System (CARS) closed	01/23/2023	01/24/2023
	Date application submitted	10/17/2022	01/24/2023
	Method of submission	CARS	01/24/2023
	Within receipt period	YES	01/24/2023
	Request for extension to submit application after CARS closed	N/A	01/24/2023
	Request for extension for late application submission accepted	N/A	01/24/2023
	Submission of application fee	YES	05/04/2023
	Receipt, Referral, and Assignment	Administrative review notification	11/09/2022
Donation(s) made to CPRIT / foundation		NO	01/24/2023
Assigned to primary reviewers		11/09/2022	01/24/2023
Applicant notified of review panel assignment		11/08/2022	01/24/2023
Primary Reviewer 1 COI signed		11/05/2022	01/24/2023
Primary (Advocate) Reviewer 2 COI signed		11/07/2022	01/24/2023
Primary Reviewer 3 COI signed		11/06/2022	01/24/2023
Primary Reviewer 4 COI signed		11/08/2022	01/24/2023
Primary Reviewer 5 COI signed		11/05/2022	01/24/2023
Primary Reviewer 6 COI signed		11/04/2022	01/24/2023
Primary Reviewer 7 COI signed		11/06/2022	01/24/2023
Peer Review Meeting	Primary Reviewer 8 COI signed	11/05/2022	01/24/2023
	Primary Reviewer 9 COI signed	11/07/2022	01/24/2023
	Primary Reviewer 10 COI signed	11/06/2022	01/24/2023
	Primary Reviewer 1 critique submitted	11/21/2022	01/24/2023
	Primary (Advocate) Reviewer 2 critique submitted	12/01/2022	01/24/2023
	Primary Reviewer 3 critique submitted	11/28/2022	01/24/2023
	Primary Reviewer 4 critique submitted	11/26/2022	01/24/2023
	Primary Reviewer 5 critique submitted	11/26/2022	01/24/2023
	Primary Reviewer 6 critique submitted	11/25/2022	01/24/2023
	Primary Reviewer 7 critique submitted	11/15/2022	01/24/2023
	Primary Reviewer 8 critique submitted	11/24/2022	01/24/2023
	Primary Reviewer 9 critique submitted	11/27/2022	01/24/2023
	Primary Reviewer 10 critique submitted	11/26/2022	01/24/2023
	COI indicated by non-primary reviewer	NONE	01/24/2023
COI recused from participation	N/A	01/24/2023	
Peer Review Meeting	12/13/2022	01/24/2023	
Post review statements signed	12/13/2022	01/24/2023	
Third Party Observer Report	12/21/2022	01/17/2023	
Score report delivered to CPDO	12/20/2022	01/24/2023	
Recommended for due diligence and IP review	YES	01/24/2023	
Due Diligence and IP Review	Final due diligence review submitted to PDRC	01/06/2023	03/22/2023
	Intellectual Property conflict check	11/23/2022	03/22/2023
	Final intellectual property review submitted	01/17/2023	03/22/2023
	COI indicated by reviewer	NONE	01/24/2023
	COI recused from participation	N/A	01/24/2023
	Due Diligence Meeting	01/20/2023	01/24/2023
	Third Party Observer Report	01/25/2023	03/24/2023
Recommended for grant award	YES	01/24/2023	
Final PDRC Recommendation	COI indicated by PDRC member	N/A	01/24/2023
	COI indicated by PDRC member	Jack Geltosky	01/24/2023
	COI recused from participation	YES	01/24/2023
	Due Diligence Evaluation Meeting / PDRC Meeting	N/A	01/24/2023
	PDRC Meeting	01/23/2023	01/24/2023
	Third Party Observer Report	01/25/2023	02/07/2023
	Recommended for grant award	YES	01/24/2023
	PDRC Chair Notification to PIC and OC	01/30/2023	02/07/2023
PIC Review	COI indicated by PIC member	N/A	05/03/2023
	COI recused from participation	N/A	05/03/2023
	PIC Review Meeting	02/01/2023	05/03/2023
	Recommended for grant award	Other: Deferred	05/03/2023
	COI indicated by PIC member	None	05/04/2023
	COI recused from participation	N/A	05/04/2023
	PIC Review Meeting	05/04/2023	05/04/2023
Recommended for grant award	YES	05/04/2023	
Oversight Committee Approval	CEO Notification to Oversight Committee	05/08/2023	05/18/2023
	COI Indicated by Oversight Committee member	None	05/18/2023
	COI Recused from participation	N/A	05/18/2023
	Donation(s) made to CPRIT / foundation	NO	05/18/2023
	Presented to CPRIT Oversight Committee	05/17/2023	05/18/2023
	Award approved by Oversight Committee	YES	05/18/2023
	Authority to advance funds requested	YES	05/18/2023
Advance authority approved by Oversight Committee	YES	05/18/2023	

# CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

## APPLICATION PEDIGREE

Date and time exported: 05/24/2023 01:37 PM CT

**FY:** 2023  
**CYCLE:** 1  
**PROGRAM:** Product Development  
**MECHANISM:** Texas Therapeutics Company Full Awards for Product Development Research  
**APPLICATION ID:** DP230071  
**APPLICATION TITLE:** Clinical development of a novel CD127 antibody for treating patients with relapsed/refractory Acute Lymphoblastic Leukemia (ALL)  
**APPLICANT NAME:** Varadhachary, Atul  
**ORGANIZATION:** Allterum Therapeutics, LLC  
**PANEL NAME:** 23.1 Product Development Panel-9

Category	Compliance Requirement	Information	Attestation Date
<b>Pre-Receipt</b>	RFA approved by CPDO	08/24/2022	01/23/2023
	RFA approved by CPDO (revised)	10/10/2022	01/23/2023
	RFA approved by CPDO (2nd revision)	02/01/2023	02/01/2023
	RFA published in Texas.gov eGrants	08/25/2022	01/23/2023
	CPRIT Application Receipt System (CARS) opened	08/24/2022	01/23/2023
	CPRIT Application Receipt System closed - Cycle 1	11/01/2022	01/24/2023
	CPRIT Application Receipt System (CARS) closed	01/23/2023	01/24/2023
	Date application submitted	10/17/2022	01/24/2023
	Method of submission	CARS	01/24/2023
	Within receipt period	YES	01/24/2023
	Request for extension to submit application after CARS closed	N/A	01/24/2023
	Request for extension for late application submission accepted	N/A	01/24/2023
	Submission of application fee	YES	05/04/2023
	<b>Receipt, Referral, and Assignment</b>	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	01/24/2023
Assigned to primary reviewers		11/10/2022	01/24/2023
Applicant notified of review panel assignment		11/08/2022	01/24/2023
Primary Reviewer 1 COI signed		11/05/2022	01/24/2023
Primary (Advocate) Reviewer 2 COI signed		11/04/2022	01/24/2023
Primary Reviewer 3 COI signed		11/09/2022	01/24/2023
Primary Reviewer 4 COI signed		11/05/2022	01/24/2023
Primary Reviewer 5 COI signed		11/05/2022	01/24/2023
Primary Reviewer 6 COI signed		11/04/2022	01/24/2023
Primary Reviewer 7 COI signed		11/10/2022	01/24/2023
<b>Peer Review Meeting</b>	Primary Reviewer 1 critique submitted	11/25/2022	01/24/2023
	Primary (Advocate) Reviewer 2 critique submitted	11/20/2022	01/24/2023
	Primary Reviewer 3 critique submitted	11/19/2022	01/24/2023
	Primary Reviewer 4 critique submitted	11/17/2022	01/24/2023
	Primary Reviewer 5 critique submitted	11/21/2022	01/24/2023
	Primary Reviewer 6 critique submitted	11/14/2022	01/24/2023
	Primary Reviewer 7 critique submitted	11/27/2022	01/24/2023
	COI indicated by non-primary reviewer	NONE	01/24/2023
	COI recused from participation	N/A	01/24/2023
	Peer Review Meeting	12/16/2022	01/24/2023
	Post review statements signed	12/16/2022	01/24/2023
	Third Party Observer Report	12/21/2022	01/17/2023
	Score report delivered to CPDO	12/20/2022	01/24/2023
Recommended for due diligence and IP review	YES	01/24/2023	
<b>Due Diligence and IP Review</b>	Final due diligence review submitted to PDRC	01/06/2023	03/22/2023
	Intellectual Property conflict check	12/02/2022	03/22/2023
	Final intellectual property review submitted	01/09/2023	03/22/2023
	COI indicated by reviewer	NONE	01/24/2023
	COI recused from participation	N/A	01/24/2023
	Due Diligence Meeting	01/13/2023	01/24/2023
	Third Party Observer Report	01/18/2023	01/24/2023
Recommended for grant award	YES	01/24/2023	
<b>Final PDRC Recommendation</b>	COI indicated by PDRC member	NONE	01/24/2023
	COI recused from participation	N/A	01/24/2023
	Due Diligence Evaluation Meeting / PDRC Meeting	N/A	01/24/2023
	PDRC Meeting	01/23/2023	01/24/2023
	Third Party Observer Report	01/25/2023	02/07/2023
	Recommended for grant award	YES	01/24/2023
<b>PIC Review</b>	PDRC Chair Notification to PIC and OC	01/30/2023	02/07/2023
	COI indicated by PIC member	N/A	05/03/2023
	COI recused from participation	N/A	05/03/2023
	PIC Review Meeting	02/01/2023	05/03/2023
	Recommended for grant award	Other: Deferred	05/03/2023
	COI indicated by PIC member	None	05/04/2023
	COI recused from participation	N/A	05/04/2023
	PIC Review Meeting	05/03/2023	05/04/2023
Recommended for grant award	YES	05/04/2023	
<b>Oversight Committee Approval</b>	CEO Notification to Oversight Committee	05/08/2023	05/18/2023
	COI Indicated by Oversight Committee member	None	05/18/2023
	COI Recused from participation	N/A	05/18/2023
	Donation(s) made to CPRIT / foundation	NO	05/18/2023
	Presented to CPRIT Oversight Committee	05/17/2023	05/18/2023
	Award approved by Oversight Committee	YES	05/18/2023
	Authority to advance funds requested	YES	05/18/2023
	Advance authority approved by Oversight Committee	YES	05/18/2023



**CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS**

**APPLICATION PEDIGREE**

Date and time exported: 05/24/2023 01:37 PM CT

**FY:** 2023  
**CYCLE:** 1  
**PROGRAM:** Product Development  
**MECHANISM:** Texas Therapeutics Company Full Awards for Product Development Research  
**APPLICATION ID:** DP230076  
**APPLICATION TITLE:** OncoResponse OR502 anti-LILRB2 monoclonal antibody Phase 1-2 clinical study  
**APPLICANT NAME:** Stocks, Clifford J  
**ORGANIZATION:** OncoResponse  
**PANEL NAME:** 23.1 Product Development Panel-8

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA approved by CPDO	08/24/2022	01/23/2023
	RFA approved by CPDO (revised)	10/10/2022	01/23/2023
	RFA approved by CPDO (2nd revision)	02/01/2023	02/01/2023
	RFA published in Texas.gov eGrants	08/25/2022	01/23/2023
	CPRIT Application Receipt System (CARS) opened	08/24/2022	01/23/2023
	CPRIT Application Receipt System closed - Cycle 1	11/01/2022	01/24/2023
	CPRIT Application Receipt System (CARS) closed	01/23/2023	01/24/2023
	Date application submitted	10/18/2022	01/24/2023
	Method of submission	CARS	01/24/2023
	Within receipt period	YES	01/24/2023
	Request for extension to submit application after CARS closed	N/A	01/24/2023
	Request for extension for late application submission accepted	N/A	01/24/2023
	Submission of application fee	YES	05/04/2023
Receipt, Referral, and Assignment	Administrative review notification	N/A	01/24/2023
	Donation(s) made to CPRIT / foundation	NO	01/24/2023
	Assigned to primary reviewers	11/10/2022	01/24/2023
	Applicant notified of review panel assignment	11/08/2022	01/24/2023
	Primary Reviewer 1 COI signed	11/04/2022	01/24/2023
	Primary (Advocate) Reviewer 2 COI signed	11/04/2022	01/24/2023
	Primary Reviewer 3 COI signed	11/04/2022	01/24/2023
	Primary Reviewer 4 COI signed	11/10/2022	01/24/2023
	Primary Reviewer 5 COI signed	11/09/2022	01/24/2023
	Primary Reviewer 6 COI signed	11/04/2022	01/24/2023
Peer Review Meeting	Primary Reviewer 7 COI signed	11/06/2022	01/24/2023
	Primary Reviewer 8 COI signed	11/04/2022	01/24/2023
	Primary Reviewer 1 critique submitted	11/20/2022	01/24/2023
	Primary (Advocate) Reviewer 2 critique submitted	11/26/2022	01/24/2023
	Primary Reviewer 3 critique submitted	11/27/2022	01/24/2023
	Primary Reviewer 4 critique submitted	11/29/2022	01/24/2023
	Primary Reviewer 5 critique submitted	11/25/2022	01/24/2023
	Primary Reviewer 6 critique submitted	12/01/2022	01/24/2023
	Primary Reviewer 7 critique submitted	11/27/2022	01/24/2023
	Primary Reviewer 8 critique submitted	11/27/2022	01/24/2023
	COI indicated by non-primary reviewer	NONE	01/24/2023
	COI recused from participation	N/A	01/24/2023
	Peer Review Meeting	12/15/2022	01/24/2023
Post review statements signed	12/16/2022	01/24/2023	
Third Party Observer Report	12/21/2022	01/17/2023	
Score report delivered to CPDO	12/20/2022	01/24/2023	
Recommended for due diligence and IP review	YES	01/24/2023	
Due Diligence and IP Review	Final due diligence review submitted to PDRC	01/06/2023	03/22/2023
	Intellectual Property conflict check	12/02/2022	03/22/2023
	Final intellectual property review submitted	01/06/2023	03/22/2023
	COI indicated by reviewer	NONE	01/24/2023
	COI recused from participation	N/A	01/24/2023
	Due Diligence Meeting	01/18/2023	01/24/2023
	Third Party Observer Report	01/25/2023	05/03/2023
Recommended for grant award	YES	01/24/2023	
Final PDRC Recommendation	COI indicated by PDRC member	N/A	01/24/2023
	COI indicated by PDRC member	Kristine Swiderek	01/24/2023
	COI recused from participation	YES	01/24/2023
	Due Diligence Evaluation Meeting / PDRC Meeting	N/A	01/24/2023
	PDRC Meeting	01/23/2023	01/24/2023
	Third Party Observer Report	01/25/2023	02/07/2023
	Recommended for grant award	YES	01/24/2023
PDRC Chair Notification to PIC and OC	01/30/2023	02/07/2023	
PIC Review	COI indicated by PIC member	N/A	05/03/2023
	COI recused from participation	N/A	05/03/2023
	PIC Review Meeting	02/01/2023	05/03/2023
	Recommended for grant award	Other: Deferred	05/03/2023
	COI indicated by PIC member	None	05/04/2023
	COI recused from participation	N/A	05/04/2023
	PIC Review Meeting	05/03/2023	05/04/2023
Recommended for grant award	YES	05/04/2023	
Oversight Committee Approval	CEO Notification to Oversight Committee	05/08/2023	05/18/2023
	COI Indicated by Oversight Committee member	None	05/18/2023
	COI Recused from participation	N/A	05/18/2023
	Donation(s) made to CPRIT / foundation	NO	05/18/2023
	Presented to CPRIT Oversight Committee	05/17/2023	05/18/2023
	Award approved by Oversight Committee	YES	05/18/2023
	Authority to advance funds requested	YES	05/18/2023
Advance authority approved by Oversight Committee	YES	05/18/2023	

**CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS**

**APPLICATION PEDIGREE**

Date and time exported: 05/24/2023 01:37 PM CT

**FY:** 2023  
**CYCLE:** 1  
**PROGRAM:** Product Development  
**MECHANISM:** Texas New Technologies Company Full Awards for Product Development Research  
**APPLICATION ID:** DP230079  
**APPLICATION TITLE:** Building Differentiated Cell Therapy Manufacturing Technologies to Attract Value- Added Biotech Partnerships  
**APPLICANT NAME:** Bock, Jason  
**ORGANIZATION:** Resilience Texas LLC dba CTMC  
**PANEL NAME:** 23.1 Product Development Panel-2

Category	Compliance Requirement	Information	Attestation Date
<b>Pre-Receipt</b>	RFA approved by CPDO	08/24/2022	01/23/2023
	RFA approved by CPDO (revised)	10/10/2022	01/23/2023
	RFA approved by CPDO (2nd revision)	02/01/2023	02/01/2023
	RFA published in Texas.gov eGrants	08/25/2022	01/23/2023
	CPRIT Application Receipt System (CARS) opened	08/24/2022	01/23/2023
	CPRIT Application Receipt System closed - Cycle 1	11/01/2022	01/24/2023
	CPRIT Application Receipt System (CARS) closed	01/23/2023	01/24/2023
	Date application submitted	10/23/2022	01/24/2023
	Method of submission	CARS	01/24/2023
	Within receipt period	YES	01/24/2023
	Request for extension to submit application after CARS closed	N/A	01/24/2023
	Request for extension for late application submission accepted	N/A	01/24/2023
	Submission of application fee	YES	05/04/2023
	<b>Receipt, Referral, and Assignment</b>	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	01/24/2023
Assigned to primary reviewers		11/10/2022	01/24/2023
Applicant notified of review panel assignment		11/08/2022	01/24/2023
Primary Reviewer 1 COI signed		11/04/2022	01/24/2023
Primary (Advocate) Reviewer 2 COI signed		11/04/2022	01/24/2023
Primary Reviewer 3 COI signed		11/07/2022	01/24/2023
Primary Reviewer 4 COI signed		11/04/2022	01/24/2023
Primary Reviewer 5 COI signed		11/05/2022	01/24/2023
Primary Reviewer 6 COI signed		11/10/2022	01/24/2023
<b>Peer Review Meeting</b>	Primary Reviewer 7 COI signed	11/06/2022	01/24/2023
	Primary Reviewer 1 critique submitted	11/21/2022	01/24/2023
	Primary (Advocate) Reviewer 2 critique submitted	11/18/2022	01/24/2023
	Primary Reviewer 3 critique submitted	11/27/2022	01/24/2023
	Primary Reviewer 4 critique submitted	12/05/2022	01/24/2023
	Primary Reviewer 5 critique submitted	11/26/2022	01/24/2023
	Primary Reviewer 6 critique submitted	11/29/2022	01/24/2023
	Primary Reviewer 7 critique submitted	11/27/2022	01/24/2023
	COI indicated by non-primary reviewer	NONE	01/24/2023
	COI recused from participation	N/A	01/24/2023
	Peer Review Meeting	12/12/2022	01/24/2023
	Post review statements signed	12/12/2022	01/24/2023
	Third Party Observer Report	12/21/2022	01/17/2023
<b>Due Diligence and IP Review</b>	Score report delivered to CPDO	12/20/2022	01/24/2023
	Recommended for due diligence and IP review	YES	01/24/2023
	Final due diligence review submitted to PDRC	01/06/2023	04/24/2023
	Intellectual Property conflict check	11/23/2022	04/27/2023
	Intellectual Property conflict check	12/02/2022	04/27/2023
	Final intellectual property review submitted	01/13/2023	04/24/2023
	COI indicated by reviewer	NONE	01/24/2023
<b>Final PDRC Recommendation</b>	COI recused from participation	N/A	01/24/2023
	Due Diligence Meeting	01/18/2023	01/24/2023
	Third Party Observer Report	01/25/2023	03/24/2023
	Recommended for grant award	YES	01/24/2023
	COI indicated by PDRC member	NONE	01/24/2023
	COI recused from participation	N/A	01/24/2023
	Due Diligence Evaluation Meeting / PDRC Meeting	N/A	01/24/2023
<b>PIC Review</b>	PDRC Meeting	01/23/2023	01/24/2023
	Third Party Observer Report	01/25/2023	02/07/2023
	Recommended for grant award	YES	01/24/2023
	PDRC Chair Notification to PIC and OC	01/30/2023	02/07/2023
	COI indicated by PIC member	N/A	05/03/2023
	COI recused from participation	N/A	05/03/2023
	PIC Review Meeting	02/01/2023	05/03/2023
	Recommended for grant award	Other: Deferred	05/03/2023
	COI indicated by PIC member	None	05/04/2023
	COI recused from participation	N/A	05/04/2023
<b>Oversight Committee Approval</b>	PIC Review Meeting	05/03/2023	05/04/2023
	Recommended for grant award	YES	05/04/2023
	CEO Notification to Oversight Committee	05/08/2023	05/18/2023
	COI Indicated by Oversight Committee member	None	05/18/2023
	COI Recused from participation	N/A	05/18/2023
	Donation(s) made to CPRIT / foundation	NO	05/18/2023
	Presented to CPRIT Oversight Committee	05/17/2023	05/18/2023
	Award approved by Oversight Committee	YES	05/18/2023
<b>Comments:</b>	Authority to advance funds requested	YES	05/18/2023
	Advance authority approved by Oversight Committee	YES	05/18/2023

Comment

Updated status on 1/18/23 to reflect new review process: Peer Review meeting to Due Diligence meeting.

# CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

## APPLICATION PEDIGREE

Date and time exported: 05/24/2023 01:37 PM CT

**FY:** 2023  
**CYCLE:** 1  
**PROGRAM:** Recruitment  
**MECHANISM:** Recruitment of Established Investigators  
**APPLICATION ID:** RR230029  
**APPLICATION TITLE:** Recruitment of Established Investigators - Dr. King  
**APPLICANT NAME:** Nakhleh, Luay  
**ORGANIZATION:** Rice University  
**PANEL NAME:** Recruitment FY23\_Cycle 4

Category	Compliance Requirement	Information	Attestation Date
<b>Pre-Receipt</b>	<b>RFA Approved by CSO</b>	<b>06/21/2022</b>	10/07/2022
	<b>RFA published in Texas.gov eGrants</b>	<b>06/21/2022</b>	10/07/2022
	<b>CPRIT Application Receipt Cycle opened</b>	<b>12/21/2022</b>	04/05/2023
	<b>CPRIT Application Receipt Cycle closed</b>	<b>02/21/2023</b>	04/05/2023
	<b>Date application submitted</b>	<b>02/20/2023</b>	04/05/2023
	<b>Method of submission</b>	<b>CARS</b>	04/05/2023
	<b>Within receipt period</b>	<b>YES</b>	04/05/2023
	<b>Receipt, Referral, and Assignment</b>	<b>Administrative review notification</b>	<b>N/A</b>
<b>Donation(s) made to CPRIT / foundation</b>		<b>NO</b>	04/05/2023
<b>Assigned to primary reviewers</b>		<b>03/02/2023</b>	04/05/2023
<b>Applicant notified of review panel assignment</b>		<b>N/A</b>	04/05/2023
<b>Primary Reviewer 1 COI signed</b>		<b>03/01/2023</b>	04/05/2023
<b>Primary Reviewer 2 COI signed</b>		<b>02/24/2023</b>	04/05/2023
<b>Peer Review Meeting</b>		<b>Primary Reviewer 1 critique submitted</b>	<b>03/13/2023</b>
	<b>Primary Reviewer 2 critique submitted</b>	<b>03/14/2023</b>	04/05/2023
	<b>COI indicated by non-primary reviewer</b>	<b>NONE</b>	04/05/2023
	<b>COI recused from participation</b>	<b>N/A</b>	04/05/2023
	<b>Discussed at Peer Review Meeting</b>	<b>YES</b>	04/05/2023
	<b>Peer Review Meeting</b>	<b>03/16/2023</b>	04/05/2023
	<b>Post review statements signed</b>	<b>03/27/2023</b>	04/05/2023
	<b>Third Party Observer Report</b>	<b>03/20/2023</b>	04/05/2023
	<b>Score report delivered to CSO</b>	<b>03/24/2023</b>	04/05/2023
	<b>Recommended for SRC review</b>	<b>YES</b>	04/05/2023
	<b>Final SRC Recommendation</b>	<b>COI indicated by SRC member</b>	<b>NONE</b>
<b>COI recused from participation</b>		<b>N/A</b>	04/05/2023
<b>SRC Meeting</b>		<b>03/16/2023</b>	04/05/2023
<b>Third Party Observer Report</b>		<b>03/20/2023</b>	04/05/2023
<b>Recommended for grant award</b>		<b>YES</b>	04/05/2023
<b>SRC Chair Notification to PIC and OC</b>		<b>04/14/2023</b>	04/21/2023
<b>PIC Review</b>	<b>Candidate not accepted position prior to SRC date</b>	<b>YES</b>	05/03/2023
	<b>COI indicated by PIC member</b>	<b>None</b>	05/03/2023
	<b>COI recused from participation</b>	<b>N/A</b>	05/03/2023
	<b>PIC Review Meeting</b>	<b>05/03/2023</b>	05/03/2023
	<b>Recommended for grant award</b>	<b>YES</b>	05/03/2023
<b>Oversight Committee Approval</b>	<b>CEO Notification to Oversight Committee</b>	<b>05/08/2023</b>	05/18/2023
	<b>COI Indicated by Oversight Committee member</b>	<b>None</b>	05/18/2023
	<b>COI Recused from participation</b>	<b>N/A</b>	05/18/2023
	<b>Donation(s) made to CPRIT / foundation</b>	<b>NO</b>	05/18/2023
	<b>Presented to CPRIT Oversight Committee</b>	<b>05/17/2023</b>	05/18/2023
	<b>Award approved by Oversight Committee</b>	<b>YES</b>	05/18/2023
	<b>Authority to advance funds requested</b>	<b>NO</b>	05/18/2023
	<b>Advance authority approved by Oversight Committee</b>	<b>NO</b>	05/18/2023

CPRIT maintains the identity of the attesting party.



# CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

## APPLICATION PEDIGREE

Date and time exported: 05/24/2023 01:41 PM CT

**FY:** 2023  
**CYCLE:** 1  
**PROGRAM:** Recruitment  
**MECHANISM:** Recruitment of First-Time, Tenure-Track Faculty Members  
**APPLICATION ID:** RR230031  
**APPLICATION TITLE:** Nomination of Dian Yang, Ph.D. for a CPRIT Recruitment of a First-Time Tenure- Track Faculty Member Award Investigator  
**APPLICANT NAME:** Lee, W. P. Andrew  
**ORGANIZATION:** The University of Texas Southwestern Medical Center  
**PANEL NAME:** Recruitment FY23\_Cycle 4

Category	Compliance Requirement	Information	Attestation Date
<b>Pre-Receipt</b>	<b>RFA Approved by CSO</b>	<b>06/21/2022</b>	10/07/2022
	<b>RFA published in Texas.gov eGrants</b>	<b>06/21/2022</b>	10/07/2022
	<b>CPRIT Application Receipt Cycle opened</b>	<b>12/21/2022</b>	04/05/2023
	<b>CPRIT Application Receipt Cycle closed</b>	<b>02/21/2023</b>	04/05/2023
	<b>Date application submitted</b>	<b>02/20/2023</b>	04/05/2023
	<b>Method of submission</b>	<b>CARS</b>	04/05/2023
	<b>Within receipt period</b>	<b>YES</b>	04/05/2023
	<b>Receipt, Referral, and Assignment</b>	<b>Administrative review notification</b>	<b>N/A</b>
<b>Donation(s) made to CPRIT / foundation</b>		<b>NO</b>	04/05/2023
<b>Assigned to primary reviewers</b>		<b>03/02/2023</b>	04/05/2023
<b>Applicant notified of review panel assignment</b>		<b>N/A</b>	04/05/2023
<b>Primary Reviewer 1 COI signed</b>		<b>02/24/2023</b>	04/05/2023
<b>Primary Reviewer 2 COI signed</b>		<b>02/25/2023</b>	04/05/2023
<b>Peer Review Meeting</b>		<b>Primary Reviewer 1 critique submitted</b>	<b>03/14/2023</b>
	<b>Primary Reviewer 2 critique submitted</b>	<b>03/07/2023</b>	04/05/2023
	<b>COI indicated by non-primary reviewer</b>	<b>NONE</b>	04/05/2023
	<b>COI recused from participation</b>	<b>N/A</b>	04/05/2023
	<b>Discussed at Peer Review Meeting</b>	<b>YES</b>	04/05/2023
	<b>Peer Review Meeting</b>	<b>03/16/2023</b>	04/05/2023
	<b>Post review statements signed</b>	<b>03/27/2023</b>	04/05/2023
	<b>Third Party Observer Report</b>	<b>03/20/2023</b>	04/05/2023
	<b>Score report delivered to CSO</b>	<b>03/24/2023</b>	04/05/2023
	<b>Recommended for SRC review</b>	<b>YES</b>	04/05/2023
	<b>Final SRC Recommendation</b>	<b>COI indicated by SRC member</b>	<b>NONE</b>
<b>COI recused from participation</b>		<b>N/A</b>	04/05/2023
<b>SRC Meeting</b>		<b>03/16/2023</b>	04/05/2023
<b>Third Party Observer Report</b>		<b>03/20/2023</b>	04/05/2023
<b>Recommended for grant award</b>		<b>YES</b>	04/05/2023
<b>SRC Chair Notification to PIC and OC</b>		<b>04/14/2023</b>	04/21/2023
<b>PIC Review</b>	<b>Candidate not accepted asst. prof. tenure track position prior to SRC date</b>	<b>YES</b>	05/03/2023
	<b>COI indicated by PIC member</b>	<b>None</b>	05/03/2023
	<b>COI recused from participation</b>	<b>N/A</b>	05/03/2023
	<b>PIC Review Meeting</b>	<b>05/03/2023</b>	05/03/2023
	<b>Recommended for grant award</b>	<b>YES</b>	05/03/2023
<b>Oversight Committee Approval</b>	<b>CEO Notification to Oversight Committee</b>	<b>05/08/2023</b>	05/18/2023
	<b>COI Indicated by Oversight Committee member</b>	<b>None</b>	05/18/2023
	<b>COI Recused from participation</b>	<b>N/A</b>	05/18/2023
	<b>Donation(s) made to CPRIT / foundation</b>	<b>NO</b>	05/18/2023
	<b>Presented to CPRIT Oversight Committee</b>	<b>05/17/2023</b>	05/18/2023
	<b>Award approved by Oversight Committee</b>	<b>YES</b>	05/18/2023
	<b>Authority to advance funds requested</b>	<b>NO</b>	05/18/2023
	<b>Advance authority approved by Oversight Committee</b>	<b>NO</b>	05/18/2023

CPRIT maintains the identity of the attesting party.



# CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

## APPLICATION PEDIGREE

Date and time exported: 05/24/2023 01:37 PM CT

**FY:** 2023  
**CYCLE:** 1  
**PROGRAM:** Recruitment  
**MECHANISM:** Recruitment of Established Investigators  
**APPLICATION ID:** RR230032  
**APPLICATION TITLE:** Nomination of Yuan Zhu, Ph.D. for a CPRIT Recruitment of an Established Investigator Award  
**APPLICANT NAME:** Lee, W. P. Andrew  
**ORGANIZATION:** The University of Texas Southwestern Medical Center  
**PANEL NAME:** Recruitment FY23\_Cycle 4

Category	Compliance Requirement	Information	Attestation Date
<b>Pre-Receipt</b>	<b>RFA Approved by CSO</b>	<b>06/21/2022</b>	10/07/2022
	<b>RFA published in Texas.gov eGrants</b>	<b>06/21/2022</b>	10/07/2022
	<b>CPRIT Application Receipt Cycle opened</b>	<b>12/21/2022</b>	04/05/2023
	<b>CPRIT Application Receipt Cycle closed</b>	<b>02/21/2023</b>	04/05/2023
	<b>Date application submitted</b>	<b>02/21/2023</b>	04/05/2023
	<b>Method of submission</b>	<b>CARS</b>	04/05/2023
	<b>Within receipt period</b>	<b>YES</b>	04/05/2023
	<b>Receipt, Referral, and Assignment</b>	<b>Administrative review notification</b>	<b>02/27/2023</b>
<b>Donation(s) made to CPRIT / foundation</b>		<b>NO</b>	04/05/2023
<b>Assigned to primary reviewers</b>		<b>03/02/2023</b>	04/05/2023
<b>Applicant notified of review panel assignment</b>		<b>N/A</b>	04/05/2023
<b>Primary Reviewer 1 COI signed</b>		<b>02/24/2023</b>	04/05/2023
<b>Primary Reviewer 2 COI signed</b>		<b>03/01/2023</b>	04/05/2023
<b>Peer Review Meeting</b>		<b>Primary Reviewer 1 critique submitted</b>	<b>03/14/2023</b>
	<b>Primary Reviewer 2 critique submitted</b>	<b>03/14/2023</b>	04/05/2023
	<b>COI indicated by non-primary reviewer</b>	<b>Eric Fearon</b>	04/05/2023
	<b>COI recused from participation</b>	<b>YES</b>	04/05/2023
	<b>Discussed at Peer Review Meeting</b>	<b>YES</b>	04/05/2023
	<b>Peer Review Meeting</b>	<b>03/16/2023</b>	04/05/2023
	<b>Post review statements signed</b>	<b>03/27/2023</b>	04/05/2023
	<b>Third Party Observer Report</b>	<b>03/20/2023</b>	04/05/2023
	<b>Score report delivered to CSO</b>	<b>03/24/2023</b>	04/05/2023
	<b>Recommended for SRC review</b>	<b>YES</b>	04/05/2023
	<b>Final SRC Recommendation</b>	<b>COI indicated by SRC member</b>	<b>Eric Fearon</b>
<b>COI recused from participation</b>		<b>YES</b>	04/05/2023
<b>SRC Meeting</b>		<b>03/16/2023</b>	04/05/2023
<b>Third Party Observer Report</b>		<b>03/20/2023</b>	04/05/2023
<b>Recommended for grant award</b>		<b>YES</b>	04/05/2023
<b>SRC Chair Notification to PIC and OC</b>		<b>04/14/2023</b>	04/21/2023
<b>PIC Review</b>	<b>Candidate not accepted position prior to SRC date</b>	<b>YES</b>	05/03/2023
	<b>COI indicated by PIC member</b>	<b>None</b>	05/03/2023
	<b>COI recused from participation</b>	<b>N/A</b>	05/03/2023
	<b>PIC Review Meeting</b>	<b>05/03/2023</b>	05/03/2023
	<b>Recommended for grant award</b>	<b>YES</b>	05/03/2023
<b>Oversight Committee Approval</b>	<b>CEO Notification to Oversight Committee</b>	<b>05/08/2023</b>	05/18/2023
	<b>COI Indicated by Oversight Committee member</b>	<b>None</b>	05/18/2023
	<b>COI Recused from participation</b>	<b>N/A</b>	05/18/2023
	<b>Donation(s) made to CPRIT / foundation</b>	<b>NO</b>	05/18/2023
	<b>Presented to CPRIT Oversight Committee</b>	<b>05/17/2023</b>	05/18/2023
	<b>Award approved by Oversight Committee</b>	<b>YES</b>	05/18/2023
	<b>Authority to advance funds requested</b>	<b>NO</b>	05/18/2023
	<b>Advance authority approved by Oversight Committee</b>	<b>NO</b>	05/18/2023

CPRIT maintains the identity of the attesting party.